^
    Back
    Association details:
    Biomarker:FGFR fusion
    Cancer:Solid Tumor
    Drug:ABSK121 (pan-FGFR inhib)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR 2023
    Title:

    Discovery and characterization of a next-generation FGFR inhibitor overcoming FGFR resistant mutations

    Published date:
    03/15/2023
    Excerpt:
    In cell lines harboring FGFR amplification, fusions, or resistant mutations, ABSK121 demonstrated strong anti-proliferation activity as well as strong inhibition of FGFR downstream signaling activities.